Publication | Open Access
Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19
177
Citations
81
References
2021
Year
To understand how a protective immune response against SARS-CoV-2 develops over time, we integrated phenotypic, transcriptional and repertoire analyses on PBMCs from mild and severe COVID-19 patients during and after infection, and compared them to healthy donors (HD). A type I IFN-response signature marked all the immune populations from severe patients during the infection. Humoral immunity was dominated by IgG production primarily against the RBD and N proteins, with neutralizing antibody titers increasing post infection and with disease severity. Memory B cells, including an atypical FCRL5<sup>+</sup> T-BET<sup>+</sup> memory subset, increased during the infection, especially in patients with mild disease. A significant reduction of effector memory, CD8<sup>+</sup> T cells frequency characterized patients with severe disease. Despite such impairment, we observed robust clonal expansion of CD8<sup>+</sup> T lymphocytes, while CD4<sup>+</sup> T cells were less expanded and skewed toward T<sub>CM</sub> and T<sub>H</sub>2-like phenotypes. MAIT cells were also expanded, but only in patients with mild disease. Terminally differentiated CD8<sup>+</sup> GZMB<sup>+</sup> effector cells were clonally expanded both during the infection and post-infection, while CD8<sup>+</sup> GZMK<sup>+</sup> lymphocytes were more expanded post-infection and represented <i>bona fide</i> memory precursor effector cells. TCR repertoire analysis revealed that only highly proliferating T cell clonotypes, which included SARS-CoV-2-specific cells, were maintained post-infection and shared between the CD8<sup>+</sup> GZMB<sup>+</sup> and GZMK<sup>+</sup> subsets. Overall, this study describes the development of immunity against SARS-CoV-2 and identifies an effector CD8<sup>+</sup> T cell population with memory precursor-like features.
| Year | Citations | |
|---|---|---|
Page 1
Page 1